AETHLON MEDICAL Business Summary

Aethlon Medical Inc (AEMD) is a clinical-stage medical technology company that operates primarily through a research and development business model, currently generating nominal revenue from interest income and government grants rather than commercial product sales. The company’s core value proposition centers on its proprietary Hemopurifier®, an investigational extracorporeal device designed to selectively remove tumor-derived extracellular vesicles (EVs) and life-threatening enveloped viruses from the circulatory system. Its primary business segments are divided into Oncology, where it is currently conducting Phase I/II trials in Australia to treat advanced solid tumors, and Infectious Disease, which focuses on viral pathogens and Long COVID research. Aethlon competes directly with companies such as Cerus Corporation, Cel-Sci Corporation, and Quoin Pharmaceuticals; it occupies a specialized niche in the market as a pioneer of lectin-based affinity purification for therapeutic applications in oncology and biodefense. The current leadership team is headed by James B. Frakes, who serves as the Chief Executive Officer, Chief Financial Officer, and Secretary, bringing over 25 years of financial executive experience and an MBA from the University of Southern California. Clinical strategy is directed by Chief Medical Officer Dr. Steven LaRosa, a renowned infectious disease expert who previously led clinical development at Entasis Therapeutics and Eli Lilly, where he oversaw the Phase III trial for the only FDA-approved sepsis treatment of its time. The company was originally founded by James A. Joyce in 1999, and its current governance includes long-standing board members such as Edward G. Broenniman and biopharma veteran Angela Rossetti. Aethlon has historically secured notable non-dilutive funding from the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS), reflecting its strategic importance in public health and biodefense sectors.